Overview
- Embecta disclosed disappointing second-quarter results and cut full-year revenue guidance on May 5, 2026, a move that sent the stock down roughly 57% and underpins the investor losses alleged in the complaints.
- Lawsuits filed on behalf of shareholders who bought stock between November 25, 2025 and May 4, 2026 claim the company made false or misleading statements and presented guidance as reliable despite known headwinds in the U.S. pen-needle market.
- Multiple plaintiff firms — including Rosen, Schall Brown & Schwartz, DJS, Kaplan Fox and Bleichmar Fonti & Auld — are actively soliciting Embecta investors and warning of an August 17, 2026 deadline to move for lead-plaintiff status.
- The litigation is at an early procedural stage with no class certified and the immediate next steps expected to be competing lead-plaintiff motions, possible consolidation of complaints, discovery, and briefing on class certification.
- Under the PSLRA the court-appointed lead plaintiff, often the investor with the largest loss, will direct litigation strategy and select counsel, and investors should know they are not represented by proposed class counsel unless a class is certified or they hire their own lawyer.